About the Company
We do not have any company description for Tourmaline Bio, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Tourmaline Bio, Inc.
Tourmaline Bio, Inc. (TRML)
Tourmaline Bio to Present Topline Results from the Ongoing Phase 2 TRANQUILITY Trial of Pacibekitug on May 20, 2025 NEW YORK, May 19, 2025 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline ...
Wall Street Analysts Predict a 151% Upside in Tourmaline Bio, Inc. (TRML): Here's What You Should Know
Tourmaline Bio, Inc. (TRML) closed the last trading session at $22.39, gaining 20.4% over the past four weeks, but there ...
Tourmaline Bio Reports Positive Trial Results and Strong Cash Position
Tourmaline Bio, Inc. ( ($TRML) ) has released its Q2 earnings. Here is a breakdown of the information Tourmaline Bio, Inc. presented to its ...
Tourmaline Bio, Inc.: Tourmaline Bio Reports Second Quarter 2025 Financial Results and Recent Business Highlights
Reported positive topline results from the ongoing Phase 2 TRANQUILITY trial of pacibekitug in May 2025, demonstrating rapid, deep, and durable reductions in high-sensitivity C-reactive protein with ...
Tourmaline Bio, Inc. (TRML) - Yahoo Finance Canada
– Tourmaline assembles leading experts to support the development of pacibekitug for cardiovascular diseases – – Cardiovascular Scientific Advisory Board expected to provide strategic guidance as ...
Tourmaline Bio, Inc.'s (NASDAQ:TRML) top owners are retail investors ...
If you want to know who really controls Tourmaline Bio, Inc. (NASDAQ:TRML), then you'll have to look at the makeup of its share registry. We can see that retail investors own the lion's share in ...
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically ...
Tourmaline Bio: Time For A Pause - Seeking Alpha
Shares of Tourmaline Bio, Inc. have surged 200% since its public debut in October 2023. The company's main asset, TOUR006, shows potential as a therapy for thyroid eye disease and atherosclerotic ...
Tourmaline Bio, Inc.: Tourmaline Bio Announces Positive Topline Results ...
TOURMALINE BIO INC WKN: A3EWHV|ISIN: US89157D1054|Ticker-Symbol: NASDAQ 20.06.25 | 21:59 16,650US-Dollar -1,07 % -0,180 Branche Biotechnologie Aktienmarkt NASDAQ Biotech 1-Jahres-Chart 5-Tage ...
Tourmaline Bio added to the NASDAQ Biotechnology Index
--Tourmaline Bio, Inc., a late-stage clinical biotechnology company developing transformative medicines to dramatically improve the lives of patients with life-altering immune and inflammatory ...
Analysts Set Tourmaline Bio, Inc. (NASDAQ:TRML) Target Price at $49.33
Tourmaline Bio, Inc. (NASDAQ:TRML – Get Free Report) has been assigned a consensus rating of “Buy” from the seven brokerages that are covering the firm, Marketbeat Ratings reports.
Tourmaline Bio, Inc. (TRML) - Yahoo Finance
Tourmaline Bio to Host Investor Day on Tuesday, December 10, 2024 NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology ...
Similar Companies
Loading the latest forecasts...